<DOC>
	<DOCNO>NCT02269891</DOCNO>
	<brief_summary>The purpose study assess effectiveness herbal combination product call Nu Femme , menopausal symptom peri-menopausal woman .</brief_summary>
	<brief_title>A Clinical Trial Efficacy Combination Herbal Product , Biotropics ' Nu Femme , Menopausal Symptoms Quality Life Women</brief_title>
	<detailed_description />
	<criteria>Female race age 40 55 year ( inclusive ) Experiencing perimenopause ( irregular menstrual cycle ( &gt; 3 month ) cessation menstrual period least 3 month within last 12 month ) OR woman menopause ( cessation menstrual period least 12 month ) . Perimenopausal woman must endometrial stripe &lt; 8 mm ultrasound screen menopausal woman must endometrial stripe &lt; 5 mm . Not required subject without intact uterus . Women intact cervix must pap smear normal within 12 month screen . Experiences menopausal transition symptom hot flush , sweat , sleep disturbance , migraine , anxiety , vaginal dryness sexual problem . Minimum 4 hot flash per day 28 per week Total score Menopause Rating Scale ≥17 indicate menopausal symptom moderate severe TSH screen exclude undiagnosed hyperthyroidism Willingness ability give write informed consent willingness ability understand , participate comply study requirement . Women positive mammogram Significant cardiac history include uncontrolled hypertension ( define untreated systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) current diagnosis major disease cardiovascular , hepatic , renal , gastrointestinal , pulmonary endocrine system Uncontrolled hyperlipidemia History current diagnosis breast cancer breast cancer identical twin , cancer ( except nonmelanomatous skin cancer ) diagnose less 5 year prior randomization . Subjects cancer full remission 5 year diagnosis acceptable exception breast cancer genital organ cancer ( e.g. , cervical cancer , uterine cancer , endometrial cancer , ovarian cancer ) Uncontrolled diabetes ( Type I Type II ) Uncontrolled and/or untreated thyroid disorder History current diagnosis major disease cardiovascular , hepatic , renal , gastrointestinal , pulmonary endocrine system History current diagnosis autoimmune condition , immunodeficiency gynaecological disease Clinically significant mental depression wellcontrolled opinion investigator Subject undergone major surgery within past one year prior randomization visit , except cholecystectomy , appendectomy Subject smoke 15 cigarette day History alcohol drug abuse within past year Subject demonstrate noncompliance treatment enrol experimental protocol Investigator knowledge Subject mental disability significant mental illness , legal incapacity limited legal capacity lack fitness , Investigator 's opinion , preclude subject 's participation complete study History finding undiagnosed abnormal vaginal bleeding within previous two year prior randomization visit , include condition , Investigator 's opinion likely source unpredictable vaginal bleeding ( i.e . leiomyoma endometrial polyp ) Subject uterine fibroid ( &gt; 2cm ) endometriosis . This assessment base size uterus participant assess Qualified Investigator Pregnant , breastfeeding , plan become pregnant course trial Positive urine pregnancy test result Polycystic ovary syndrome ( PCOS ) History abnormal Pap smear Significant abnormal liver function define AST and/or ALT &gt; 2 x upper limit normal ( ULN ) , and/or bilirubin &gt; 2 x ULN eGFR &lt; 60 Bleeding disorder anaemia etiology define haemoglobin ≤ 110 g/L Subject take follow medication time period specify prior screen visit study Sex hormone : Vaginal ring vaginal cream , ointment gel 1 week Transdermal topical 4 week DHEA within 24 week Natural supplement advertise hormonal effect within 4 week Oral within 4 week Intrauterine progestin implant within 8 week Progestin implant estrogen alone injection within 12 week Injected progestin estrogen androgen implant pellet within 24 week Gonadotropinreleasing hormone ( GnRH ) agonists within 24 week Selective Estrogen Receptor Modulators ( SERMs ) within 4 week Glucocorticoids Chronic high dose ( ≥ 7.5 mg prednisone per day equivalent ) past 12 week . Exceptions : Chronic low dose corticosteroid use ( &lt; 7.5 mg prednisone per day , equivalent ) permit provide subject stabilize dose least 12 week prior randomization maintains current dose dose regimen study . Acute topical , inhaled , oral ( e.g . dose pack ) use exclusionary permit course study . Antidepressant and/or antianxiety medication within 4 week unless chronic stable dose maintain great 12 week . Subject must maintain current dose dose regimen study . Use Effexor ( Venlafaxine HCl ) within 4 week exclusionary . Use Dixarit ( Clonidine HCl ) within 2 week exclusionary . Thyroid antiepileptic medication within 12 week unless chronic stable dose maintain great 12 week prior randomization . Subjects must maintain current dose dose regimen study Use Prostaglandins within 4 week Other investigational study medication within 4 week Current use propranolol Current use intrauterine device ( IUD ) Use natural health product , primrose oil , black cohosh , soy product , vitamin and/or mineral supplement within 4 week Known allergy hypersensitivity study product ingredient Subjects weight reduction program medically supervise diet . Unexplained weight loss weight gain 5 kg month prior randomization Any condition Investigator 's opinion may adversely affect subject 's ability complete study measure may pose significant risk subject</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Menopausal symptom</keyword>
	<keyword>Peri-menopause</keyword>
	<keyword>Nu Femme</keyword>
	<keyword>Labisia pumila</keyword>
	<keyword>Eurycoma longifolia</keyword>
	<keyword>Hot flash</keyword>
	<keyword>Joint pain</keyword>
</DOC>